/ARMP
ARMP Stock - Armata Pharmaceuticals, Inc.
Healthcare|BiotechnologyAMEX
$6.16+14.07%
+$0.76 (+14.07%) • Dec 19
83
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.97
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.70
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+46.1%upside
Target: $9.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ARMP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.10 – $6.22
TARGET (TP)$9.00
STOP LOSS$5.67
RISK/REWARD1:5.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.25
52W High$16.34
52W Low$0.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $5.17M | $4.53M | $5.51M | $4.47M | $823,000 |
| Gross Profit | $-29,252,000 | $3.56M | $-29,509,000 | $-15,541,000 | $-13,621,000 |
| Gross Margin | -565.4% | 78.5% | -535.7% | -347.4% | -1655.0% |
| Operating Income | $-42,436,000 | $-40,890,000 | $-36,946,000 | $-23,822,000 | $-21,587,000 |
| Net Income | $-18,916,000 | $-69,045,000 | $-36,917,000 | $-23,155,000 | $-22,181,000 |
| Net Margin | -365.6% | -1524.5% | -670.2% | -517.5% | -2695.1% |
| EPS | $-0.52 | $-1.91 | $-1.08 | $-0.96 | $-1.35 |
Company Overview
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ARMPBeat Rate
50%
Last 18 quarters
Avg Surprise
-7.0%
EPS vs Estimate
Beats / Misses
9/6
3 met exactly
Latest EPS
$-0.42
Q4 2025
EPS Surprise History
Q1 24
-57.1%
$-0.55vs$-0.35
Q2 24
-146.4%
$-0.69vs$-0.28
Q3 24
-25.0%
$-0.65vs$-0.52
Q4 24
+46.4%
$-0.15vs$-0.28
Q1 25
+34.3%
$-0.23vs$-0.35
Q2 25
+47.4%
$-0.20vs$-0.38
Q3 25
+17.9%
$-0.32vs$-0.39
Q4 25
0.0%
$-0.42vs$-0.42
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.41 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.42 | $-0.42 | 0.0% | = MET |
Q3 2025 | Aug 12, 2025 | $-0.39 | $-0.32 | +17.9% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.38 | $-0.20 | +47.4% | ✓ BEAT |
Q1 2025 | Mar 20, 2025 | $-0.35 | $-0.23 | +34.3% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.28 | $-0.15 | +46.4% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.52 | $-0.65 | -25.0% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.28 | $-0.69 | -146.4% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-0.35 | $-0.55 | -57.1% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.33 | $-0.31 | +6.1% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.35 | $-0.28 | +20.0% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.29 | $-0.40 | -37.9% | ✗ MISS |
Q1 2023 | Mar 16, 2023 | $-0.25 | $-0.29 | -16.0% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.27 | $-0.24 | +11.1% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.26 | $-0.26 | 0.0% | = MET |
Q2 2022 | May 12, 2022 | $-0.20 | $-0.30 | -50.0% | ✗ MISS |
Q1 2022 | Mar 17, 2022 | $-0.25 | $-0.23 | +8.0% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.26 | $-0.22 | +15.4% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.25 | $-0.25 | 0.0% | = MET |
Latest News
Armata Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeBenzinga•Nov 13, 2025, 12:15 PM
Armata Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeBenzinga•Nov 12, 2025, 09:49 PM
Armata Pharmaceuticals Q3 EPS $(0.74) Misses $(0.42) Estimate, Sales $1.159M Miss $1.380M Estimate
📉 NegativeBenzinga•Nov 12, 2025, 09:40 PM
Armata Pharmaceuticals Commissions Good Manufacturing Practice Production Facility In Los Angeles
📈 PositiveBenzinga•Nov 10, 2025, 12:07 PM
Armata Pharmaceuticals Inc. Shares Resume Trading
➖ NeutralBenzinga•Oct 22, 2025, 05:11 PM
Armata surges on mid-stage trial data for antibacterial agent
📈 PositiveSeeking Alpha•Oct 22, 2025, 05:05 PM
Armata Pharmaceuticals Shares Resume Trade, Then Halted Again On Circuit Breaker To The Upside, Stock Now Up 173.20%
📈 PositiveBenzinga•Oct 22, 2025, 04:28 PM
Armata Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 132.28%
📈 PositiveBenzinga•Oct 22, 2025, 04:17 PM
Armata Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 95.39%
📈 PositiveBenzinga•Oct 22, 2025, 04:03 PM
Armata Pharmaceuticals Shares Resume Trading
➖ NeutralBenzinga•Oct 22, 2025, 03:59 PM
Armata Pharmaceuticals shares are trading higher after the company announced results from its recently completed Phase 2a diSArm study of AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia.
📈 PositiveBenzinga•Oct 22, 2025, 03:49 PM
Armata Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 58.50%
📈 PositiveBenzinga•Oct 22, 2025, 03:48 PM
Armata Pharmaceuticals Bacteriophage Therapy Shows Zero Relapse In Phase 2a SAB Trial, Paving Way For Phase 3 In 2026
📈 PositiveBenzinga•Oct 22, 2025, 03:33 PM
Armata Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 19.60%
📈 PositiveBenzinga•Oct 22, 2025, 03:32 PM
Armata Pharmaceuticals Shares Resume Trade
➖ NeutralBenzinga•Oct 22, 2025, 03:30 PM
Armata Pharma Reports Results From Its Recently Completed Phase 2a diSArm Study Of AP-SA02 As A Potential Treatment For Complicated Staphylococcus Aureus Bacteremia In A Late-Breaking Oral Presentation At IDWeek 2025
📈 PositiveBenzinga•Oct 22, 2025, 03:12 PM
Armata Pharmaceuticals To Present Late-Breaking Phase 2a Data For AP-SA02 Bacteriophage Cocktail In Complicated Staphylococcus Aureus Bacteremia At IDWeek 2025 In Atlanta On Oct. 22
📈 PositiveBenzinga•Oct 14, 2025, 11:10 AM
Armata Pharmaceuticals Advances Cystic Fibrosis Infection Treatment With Phage Research
📈 PositiveBenzinga•Sep 8, 2025, 11:11 AM
Frequently Asked Questions about ARMP
What is ARMP's current stock price?
Armata Pharmaceuticals, Inc. (ARMP) is currently trading at $6.16 per share. The stock has moved +14.07% today.
What is the analyst price target for ARMP?
The average analyst price target for ARMP is $9.00, based on 1 analyst.
What sector is Armata Pharmaceuticals, Inc. in?
Armata Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the AMEX exchange.
What is ARMP's market cap?
Armata Pharmaceuticals, Inc. has a market capitalization of $0.22 billion, making it a small-cap company.
Does ARMP pay dividends?
No, Armata Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCCCC
C4 Therapeutics, Inc.
$2.03
Mkt Cap: $0.1B
CDXS
Codexis, Inc.
$1.66
Mkt Cap: $0.1B
GNFT
Genfit S.A.
$5.61
Mkt Cap: $0.3B
IMDX
Insight Molecular Diagnostics Inc.
$5.41
Mkt Cap: $0.2B
IPHA
Innate Pharma S.A.
$1.75
Mkt Cap: $0.1B
NTHI
Neonc Technologies Holdings, Inc.
$7.01
Mkt Cap: $0.1B
NVCT
Nuvectis Pharma, Inc.
$7.78
Mkt Cap: $0.2B
OABI
OmniAb, Inc.
$2.09
Mkt Cap: $0.2B
SGMO
Sangamo Therapeutics, Inc.
$0.45
Mkt Cap: $0.2B
SLS
SELLAS Life Sciences Group, Inc.
$2.36
Mkt Cap: $0.2B
Explore stocks similar to ARMP for comparison